After 1,635 days of litigation, Judge F. Dennis Saylor IV of the Massachusetts District Court dismissed Philips North America LLC’s patent infringement action against Fitbit LLC on January 12, 2024. The case, filed July 22, 2019, centered on four U.S. patents—US6013007A, US6976958B2, US8277377B2, and US7088233B2—allegedly covering health and activity monitoring technologies that Philips claimed were embodied in Fitbit’s Surge, Charge, Flex, Versa, Alta, Inspire, Ionic, and Blaze fitness trackers. The dismissal came via the Court’s Order on Renewed Motion to Dismiss and Entry of Final Judgment.

This case carries significant strategic weight for IP professionals operating in the wearable health technology space, where patent portfolios from legacy medical device companies increasingly collide with consumer electronics innovators. The outcome signals that even well-resourced plaintiffs with multi-patent assertions face substantial procedural and substantive hurdles in extended litigation campaigns, and underscores the importance of robust pre-suit claim mapping and FTO analysis before asserting legacy medical device patents against modern fitness wearables.

Case Overview

The Parties

The Patents at Issue

The four patents at issue broadly cover physiological monitoring and activity tracking technologies. US6013007A and US6976958B2 relate to methods and systems for monitoring human physical activity and physiological parameters—core functionality in both clinical actigraphy devices and consumer fitness wearables. US8277377B2 and US7088233B2 address motion sensing and data processing techniques used to infer health metrics such as sleep quality, step count, and caloric expenditure. Together, these patents represent foundational intellectual property in the automated health monitoring space that predates the consumer wearable boom.

• • US6013007A
• • US6976958B2
• • US8277377B2
• • US7088233B2

Legal Representation

Plaintiff Counsel: Foley & Lardner, LLP (lead: Andrew M. Gross)
Defendant Counsel: Desmarais LLP; Fitzgerald Knaier LLP; Goulston & Storrs PC; Paul Hastings LLP; Wolf, Greenfield & Sacks, PC (lead: Adam Steinmetz)

Litigation Timeline & Procedural History

Philips filed this action on July 22, 2019, in the District of Massachusetts—a venue with an experienced bench for complex patent matters and a court that handles significant volumes of technology patent disputes in the New England region. The case proceeded at the first-instance (district court) level before Chief Judge F. Dennis Saylor IV, meaning no claim constructions or liability findings were appealed to the Federal Circuit during the active litigation period. The four-patent assertion against Fitbit’s eight flagship consumer product lines signals this was intended as a high-stakes, multi-front enforcement campaign by Philips.

The case ran for 1,635 days—nearly four and a half years—before terminating on January 12, 2024, via a Renewed Motion to Dismiss that resulted in entry of Final Judgment. The ‘renewed’ nature of the dismissal motion is procedurally significant: it indicates an initial dismissal motion had been filed and either denied or deferred, with Fitbit ultimately prevailing on a subsequent attempt. No jury verdict or damages award was reached, and the case was dismissed rather than settled, suggesting either a fatal defect in Philips’ claims—such as patent ineligibility, lack of standing, or claim construction failure—or a strategic withdrawal tied to the parallel evolution of the parties’ business relationship following Google’s acquisition of Fitbit.

The Verdict & Legal Analysis

Outcome

The Massachusetts District Court dismissed the entirety of Philips North America LLC’s infringement action against Fitbit LLC pursuant to its Order on Renewed Motion to Dismiss and Entry of Final Judgment dated January 12, 2024 (Dkt. No. 435). No damages were awarded and no injunctive relief was granted. Because the case ended on a dismissal rather than a merits verdict, the Court made no final determination of infringement or invalidity of the four asserted patents.

Verdict Cause Analysis

The dismissal on a Renewed Motion to Dismiss points to several potential dispositive legal grounds that patent practitioners should evaluate carefully:

• A renewed dismissal motion suggests the Court initially declined to dismiss but was ultimately persuaded by supplemented arguments—commonly arising from intervening case law, new invalidity evidence, or a narrowed claim construction that eliminated the infringement theory.
• Patent eligibility under 35 U.S.C. § 101 is a frequently litigated ground for dismissal in health-monitoring and activity-tracking patent cases, where claims directed to abstract ideas of collecting and analyzing physiological data face heightened Alice/Mayo scrutiny.
• Standing or licensing defenses may have been raised if Fitbit’s defense team identified gaps in the chain of title from the original inventors to Philips North America LLC, or identified an existing license or covenant not to sue arising from the Google acquisition ecosystem.
• Claim construction outcomes at the Markman hearing stage often precipitate renewed dismissal motions when the Court’s construction of key claim terms renders non-infringement apparent as a matter of law, eliminating the need for a full trial.

Legal Significance

1. 1. The dismissal without prejudice or merits adjudication leaves the validity of all four asserted patents—US6013007A, US6976958B2, US8277377B2, and US7088233B2—unresolved, meaning Philips retains the theoretical ability to assert them in future proceedings, though prosecution history and litigation conduct may limit available claim interpretations.
2. 2. The case illustrates the increasing difficulty of asserting foundational medical-device patents against consumer wearable products when the accused devices are designed around a different technical architecture, highlighting the critical importance of claim mapping that accounts for implementation-level differences between clinical and consumer-grade systems.
3. 3. Fitbit’s deployment of five defense law firms—Desmarais LLP, Paul Hastings LLP, Wolf Greenfield & Sacks, Goulston & Storrs, and Fitzgerald Knaier—demonstrates the multi-front defensive strategy large consumer technology defendants employ, combining specialized patent litigation boutiques with local counsel and in-house coordination, a model increasingly replicated in wearable tech disputes.

Strategic Takeaways

For Patent Attorneys:

• When asserting legacy medical device patents against consumer electronics defendants, conduct granular claim-to-product mapping at the component level before filing, because courts increasingly scrutinize whether clinical-context claim language reads on consumer-grade implementations.
• Monitor the status of renewed dismissal motions in long-running district court cases—the Philips v. Fitbit trajectory shows that an initial denial of dismissal does not foreclose later success, and defendants should preserve and supplement their dismissal arguments throughout claim construction.
• Analyze the impact of corporate transactions on patent standing and licensing obligations; the Google acquisition of Fitbit may have introduced cross-licensing dynamics that altered the litigation calculus for both parties.
• Consider filing inter partes review petitions early in parallel with district court proceedings for health-monitoring patents, especially those with pre-AIA priority dates, to create invalidity leverage and potential stays of district court litigation.

For IP Professionals:

• In-house teams at wearable technology companies should conduct proactive FTO audits against Philips’ remaining active health-monitoring patent portfolio, as the dismissal of this case does not invalidate the four asserted patents and Philips may re-assert or license them against other market participants.
• Map your company’s product feature roadmap—particularly any physiological monitoring, sleep tracking, or motion sensing capabilities—against the claim scope of US6013007A, US6976958B2, US8277377B2, and US7088233B2 to assess ongoing infringement risk before commercial launch.

For R&D Teams:

• Engineering teams developing next-generation activity and health monitoring features should document design choices that technically distinguish their implementations from the clinical actigraphy methods described in Philips’ patent claims, creating a contemporaneous record that supports future non-infringement arguments.
• Consider architectural differentiation strategies such as on-device machine learning inference, sensor fusion approaches distinct from those claimed in the Philips patents, or open-source algorithm libraries with prior art provenance to reduce FTO exposure in the health-monitoring feature space.